About Debiopharm Group
Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.
Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales of $2.6 billion in 2008.
For more information on Debiopharm Group, please visit: http://www.debiopharm.com
About H. Lee Moffitt Cancer Center & Research Institute
Located in Tampa, Florida, Moffitt Cancer Center
[http://www.moffitt.org/] is an NCI [http://www.cancer.gov/] Comprehensive
Cancer Center - a designation that recognises Moffitt's excellence in
research and contributions to clinical trials, prevention and cancer control.
Moffitt currently has 15 affiliates in Florida, one in Georgia and two in
Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive
Cancer Network [http://www.nccn.org/index.asp], a prestigious alliance of the
country's leading cancer centres, and is listed in U.S. News & World Report
|SOURCE Debiopharm Group|
Copyright©2009 PR Newswire.
All rights reserved